Precision Signals

In Episode 4 of Precision Signals, Dr. Sean Khozin sits down with Daniel Arbess—investor, social entrepreneur, and healthcare innovator—to explore why the limiting factor in solving cancer and neurodegenerative diseases isn't breakthrough science, but institutional innovation.Daniel Arbess has built a career on questioning foundational assumptions across multiple domains: from analyzing Cold War nuclear policy to restructuring post-Soviet industries as the youngest-ever partner at White & Case,

In this episode of Precision Signals, Dr. Sean Khozin speaks with Dr. James Gulley, Chief of the Medical Oncology Service and Co-Director of the Center for Immuno-Oncology at the National Cancer Institute.Dr. Gulley is one of the world’s leading figures in immuno-oncology. He helped bring immune-based cancer therapies from an era of skepticism into a clinical mainstay, shaping both the science and the clinical frameworks that define the field today.Their conversation explores the critical frontiers

Dr. Michelle Longmire, physician-scientist, technologist, and CEO, cofounder of Medable; shares how early lessons in science and systems design shaped her mission to fix one of medicine’s most persistent bottlenecks: slow, fragmented, and inaccessible clinical trials.We discuss her path from autoimmune skin disease research at Stanford to building Medable into a global clinical trial infrastructure platform operating across 14 therapeutic areas, and what it takes to align technology, AI, and

What does it take for AI to move from technical innovation to real-world adoption in oncology?In the first episode of Precision Signals, Dr. Sean Khozin speaks with Dr. Cora Sternberg and Dr. Olivier Elemento—two leaders at the intersection of clinical trials, precision medicine, and computational biology.Together, they unpack the central paradox of medical AI: why so many tools are technically validated, yet so few are clinically trusted. Topics include:Why randomized clinical trials—not just